Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

River Blindness Marker Found In Patients

Diagnostics: Discovery of parasite-derived metabolite could aid effort to wipe out tropical disease

by Stu Borman
March 1, 2013 | A version of this story appeared in Volume 91, Issue 9

[+]Enlarge
Credit: Courtesy of Kim Janda
Mature version of a worm “that we excised from an infected individual when one of my group members was collecting samples,” Janda says.
Microscope image shows a mature version of worm “that we excised from an infected individual when one of my group members was collecting samples,” Janda says.
Credit: Courtesy of Kim Janda
Mature version of a worm “that we excised from an infected individual when one of my group members was collecting samples,” Janda says.

Onchocerciasis, or river blindness, is a tropical worm infection that causes blindness and other symptoms. It is treatable, and reversible, with medicine. But current immune response-based diagnostics and skin biopsies are unreliable, so it’s difficult to distinguish treated but still-infected patients from those who have been freed of the worms. That means millions of patients are re-treated repeatedly and unnecessarily—a difficult, expensive, and inefficient practice.

The discovery of a worm-based molecule in patients’ urine, by a team from Scripps Research Institute, in California, offers the possibility of a better diagnostic test. Kim D. Janda and coworkers discovered the biomarker, structurally analyzed it, and traced its provenance (Proc. Natl. Acad. Sci. USA, DOI: 10.1073/pnas.1221969110).

River blindness is caused by worm larvae carried by blackflies and then transmitted to people in fly bites. Coadministration of the antiworm drug ivermectin, often donated by Merck & Co., and the antibiotic doxycycline is a fairly effective treatment. But it doesn’t clear all patients of the worm, which can remain dormant for as long as a decade. The drugs are therefore now administered repeatedly to all those who have been treated for less than a decade.

By comparing urine from infected and noninfected Africans, Scripps postdoc Daniel Globisch found a compound that could be monitored to enable treatment to be restricted to those still infected. The Scripps team identified it as N-acetyltyramine-O,β-glucuronide, is a metabolized worm neurotransmitter that is excreted by the human host.

Urine levels of the metabolite are about six times higher in infected than in noninfected patients. It seems to be specific for the river blindness worm when tested in the presence of coinfecting parasites, but its specificity needs to be validated further. A current drawback is that the test works in African onchocerciasis patients but not in infected South Americans. However, 99.9% of river blindness currently occurs in Africa.

Another problem is that the group’s tests were carried out with liquid chromatography/mass spectrometry instruments that would be too difficult and expensive to use in the tropics. The researchers hope to develop a less expensive and more convenient version.

“This is the first clear demonstration of a parasite metabolite that can be detected in easily accessible fluid,” comments Thomas B. Nutman, deputy chief of the Laboratory of Parasitic Diseases at the National Institute of Allergy & Infectious Diseases. But it remains to be seen whether the compound “will ultimately have the kind of positive predictive value Janda and coworkers are hoping for.”

River blindness diagnostics expert Thomas Unnasch of the University of South Florida says that such a marker “is something people have been chasing for about 20 years. This is a really good first step.”

Advertisement

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.